Sign in Subscribe

liquid-biopsy

A collection of 68 issues

Blood-Based Screening Now Available Starting at Age 45

Skip to content The CRC Digest Blood-Based Screening Now Available Starting at Age 45 The newly FDA-approved SimpleScreen CRC blood test is available for adults aged 45 years and older who are at average risk for colorectal cancer. (The ASCO Post) This content is informational only and does not constitute

ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery

Skip to content The CRC Digest ctDNA Testing May Identify Who Benefits from Chemotherapy After Liver Metastasis Surgery An overall survival analysis of the phase II GALAXY study presented at ESMO GI 2026 suggests that circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer

Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRC The phase III NRG-GI004/SWOG S1610 COMMIT trial found that combining mFOLFOX6, bevacizumab, and atezolizumab may prolong progression-free survival over atezolizumab alone in first-line treatment of mismatch repair–deficient/microsatellite instability–

FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults

Skip to content The CRC Digest ● REGULATORY FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 and older at average risk, based on data from the PREEMPT CRC trial. (The ASCO Post)

Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Circulating tumor DNA dynamics predict survival in metastatic colorectal cancer In a study of 1,391 patients, those with persistent or acquired RAS and BRAF mutations in ctDNA had significantly worse overall survival than patients who maintained wild-type status, suggesting liquid biopsy monitoring

New ctDNA assay validated for minimal residual disease monitoring across solid tumors

Skip to content The CRC Digest ◇ RESEARCH New ctDNA assay validated for minimal residual disease monitoring across solid tumors The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low

ctDNA methylation profiling may predict prognosis beyond mutation testing

Skip to content The CRC Digest ◇ RESEARCH ctDNA methylation profiling may predict prognosis beyond mutation testing DNA methylation in circulating tumor DNA may provide additional prognostic information beyond mutation-based analysis by reflecting coordinated regulatory states associated with tumor behavior, including transcriptional programs and cellular plasticity. (Epigenomics) This content is informational

Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice

Skip to content The CRC Digest ▪ SCREENING Follow-Up Colonoscopy Completion After Positive Stool DNA Test in Community Practice In a real-world study of patients with positive multi-target stool DNA tests, researchers evaluated follow-up colonoscopy completion rates and advanced neoplasia findings within 365 days. (Current Medical Research and Opinion) This content

Low Cancer Risk After Negative Colonoscopy Following Positive Stool DNA Test

Skip to content The CRC Digest Low Cancer Risk After Negative Colonoscopy Following Positive Stool DNA Test Community practice data show that patients with a positive multitarget stool DNA test but negative colonoscopy had low rates of subsequent aerodigestive cancers. (Clinical and Translational Gastroenterology) This content is informational only and

ctDNA-Guided Surveillance Doubles Curative Treatment Rate for Recurrent CRC

Skip to content The CRC Digest ◆ TRIAL DATA ctDNA-Guided Surveillance Doubles Curative Treatment Rate for Recurrent CRC In the phase III FIND trial, patients monitored with circulating tumor DNA testing after surgery were twice as likely to receive curative-intent treatment when cancer recurred compared to standard surveillance (48.1% vs